{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T05:17:02Z","timestamp":1740115022296,"version":"3.37.3"},"reference-count":10,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006400","name":"Alnylam Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006400","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Cardiovascular Medicine"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.tcm.2023.03.001","type":"journal-article","created":{"date-parts":[[2023,3,12]],"date-time":"2023-03-12T22:43:54Z","timestamp":1678661034000},"page":"265-266","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Editorial commentary: Is seeing really believing? The role of the 12 lead electrocardiogram in cardiac amyloidosis"],"prefix":"10.1016","volume":"34","author":[{"given":"Jasneet","family":"Devgun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karthikeyan","family":"Ananthasubramaniam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.tcm.2023.03.001_bib0001","first-page":"E7","article-title":"Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American heart association","author":"Kittleson","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.tcm.2023.03.001_bib0002","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.jaccao.2021.07.010","article-title":"Electrophysiological manifestations of cardiac amyloidosis: JACC: cardiooncology state-of-the-art review","volume":"3","author":"Hartnett","year":"2021","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.tcm.2023.03.001_bib0003","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/joa3.12376","article-title":"Trends, burden, and impact of arrhythmia on cardiac amyloid patients: a 16-year nationwide study from 1999 to 2014","volume":"36","author":"Isath","year":"2020","journal-title":"J Arrhythm"},{"key":"10.1016\/j.tcm.2023.03.001_bib0004","article-title":"Conduction system disease in cardiac amyloidosis","author":"Assaf","year":"2023","journal-title":"Trends Cardiovasc Med"},{"key":"10.1016\/j.tcm.2023.03.001_bib0005","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.amjcard.2020.05.021","article-title":"Prevalence, incidence, and impact on mortality of conduction system disease in transthyretin cardiac amyloidosis","volume":"128","author":"Donnellan","year":"2020","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.tcm.2023.03.001_bib0006","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1161\/CIRCULATIONAHA.108.843334","article-title":"Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types","volume":"120","author":"Rapezzi","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.tcm.2023.03.001_bib0007","article-title":"Electrocardiographic features and rhythm disorders in cardiac amyloidosis","author":"Martini","year":"2023","journal-title":"Trends Cardiovasc Med"},{"key":"10.1016\/j.tcm.2023.03.001_bib0008","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jacc.2016.03.596","article-title":"Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (transthyretin amyloid outcome survey)","volume":"68","author":"Maurer","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.tcm.2023.03.001_bib0009","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1093\/eurheartj\/ehx350","article-title":"Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement","volume":"38","author":"Casta\u00f1o","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.tcm.2023.03.001_bib0010","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1161\/circ.104.14.1594","article-title":"Infusion of light chains from patients with cardiac amyloidosis causes diastolic dysfunction in isolated mouse hearts","volume":"104","author":"Liao","year":"2001","journal-title":"Circulation"}],"container-title":["Trends in Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1050173823000282?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1050173823000282?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T01:11:41Z","timestamp":1715044301000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1050173823000282"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":10,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S1050173823000282"],"URL":"https:\/\/doi.org\/10.1016\/j.tcm.2023.03.001","relation":{},"ISSN":["1050-1738"],"issn-type":[{"type":"print","value":"1050-1738"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Editorial commentary: Is seeing really believing? The role of the 12 lead electrocardiogram in cardiac amyloidosis","name":"articletitle","label":"Article Title"},{"value":"Trends in Cardiovascular Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tcm.2023.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.tcm.2023.02.006","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}